Merck KGaA Invests € 300m for New Research Centre in Darmstadt, Germany
Merck KGaA (Merck) announced an investment today of more than €300 Million ($320.8m) in a new Life Science Research Centre
Read moreMerck KGaA (Merck) announced an investment today of more than €300 Million ($320.8m) in a new Life Science Research Centre
Read moreStressMarq manufactures and offers a wide range of products specifically developed to accelerate Parkinson’s disease research. StressMarq’s cutting-edge product range
Read moreStressMarq manufactures and offers a comprehensive range of Alzheimer’s Disease Research Products. StressMarq’s product range includes Antibodies, Proteins, Immunoassays, Small
Read moreStressMarq provides a cutting-edge selection of Amyloid Beta Pre-formed Fibrils (PFFs), Oligomers, and Monomers specifically designed to facilitate advanced neurodegenerative
Read moreStressMarq has developed unique Superoxide Dismutase 1 (SOD1) Pre-formed Fibrils (PFFs) and monomers for neurodegenerative disease research, particularly valuable for
Read moreStressMarq has developed unique Transthyretin (TTR) Filaments and Monomers designed to propel research on TTR and its association with amyloid
Read moreStressMarq has developed unique alpha synuclein constructs to provide invaluable support to researchers engaged in disease model development and the
Read moreStressMarq is a pioneer in the development of tau proteins that facilitate the investigation of tau aggregation, a key characteristic
Read moreChiesi Global Rare Diseases and Protalix BioTherapeutics, Inc. have received marketing authorization from the European Commission (EC) for their drug,
Read moreThe Recombinant TEV Protease Protein His6 is a genetically optimised 28 kDa variation of the N1a protease from tobacco etch
Read more